A detailed history of Atria Wealth Solutions, Inc. transactions in Novo Nordisk A S stock. As of the latest transaction made, Atria Wealth Solutions, Inc. holds 39,668 shares of NVO stock, worth $5.65 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
39,668
Previous 37,049 7.07%
Holding current value
$5.65 Million
Previous $3.83 Million 32.91%
% of portfolio
0.06%
Previous 0.05%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$102.11 - $135.92 $267,426 - $355,974
2,619 Added 7.07%
39,668 $5.09 Million
Q4 2023

Feb 02, 2024

BUY
$87.78 - $105.45 $725,589 - $871,649
8,266 Added 28.72%
37,049 $3.83 Million
Q3 2023

Nov 08, 2023

BUY
$90.94 - $199.54 $1.55 Million - $3.4 Million
17,029 Added 144.88%
28,783 $2.62 Million
Q2 2023

Aug 03, 2023

BUY
$155.98 - $172.65 $240,521 - $266,226
1,542 Added 15.1%
11,754 $1.9 Million
Q1 2023

Aug 22, 2023

SELL
$132.34 - $159.14 $366,714 - $440,976
-2,771 Reduced 23.57%
8,983 $1.43 Million
Q1 2023

Jun 14, 2023

BUY
$132.34 - $159.14 $162,645 - $195,583
1,229 Added 13.68%
10,212 $1.63 Million
Q1 2023

May 10, 2023

SELL
$132.34 - $159.14 $399,931 - $480,921
-3,022 Reduced 25.17%
8,983 $1.43 Million
Q4 2022

Aug 30, 2023

SELL
$102.55 - $135.33 $158,132 - $208,678
-1,542 Reduced 13.12%
10,212 $1.38 Million
Q4 2022

Feb 13, 2023

BUY
$102.55 - $135.33 $585,663 - $772,869
5,711 Added 90.74%
12,005 $1.62 Million
Q3 2022

Feb 13, 2023

SELL
$95.28 - $116.93 $232,102 - $284,841
-2,436 Reduced 27.9%
6,294 $627,000
Q3 2022

Nov 14, 2022

BUY
$95.28 - $116.93 $636,470 - $781,092
6,680 Added 325.85%
8,730 $899,000
Q2 2022

Aug 15, 2022

SELL
$103.24 - $121.81 $102,001 - $120,348
-988 Reduced 32.52%
2,050 $228,000
Q1 2022

May 16, 2022

BUY
$93.1 - $112.54 $282,837 - $341,896
3,038 New
3,038 $340,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $321B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Atria Wealth Solutions, Inc. Portfolio

Follow Atria Wealth Solutions, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atria Wealth Solutions, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Atria Wealth Solutions, Inc. with notifications on news.